Maxim lowered the firm’s price target on PAVmed (PAVM) to $16 from $60 and keeps a Buy rating on the shares. The firm is adjusting its model on the stock to reflect a higher expected share count and equity dilution, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PAVM: